OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
December 09, 2020
Piramal Pharma Solutions invests in expanded potent and non-potent API development and manufacturing at its Riverview, MI facility.
November 18, 2020
The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
October 19, 2020
The lab, which is currently available to customers, can handle highly potent compounds.
August 03, 2020
Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.
June 04, 2020
CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.
Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.
May 19, 2020
HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.